ProHealth health Vitamin and Natural Supplement Store and Health
Home  |  Log In  |  My Account  |  View Cart  View Your ProHealth Vitamin and Supplement Shopping Cart
800-366-6056  |  Contact Us  |  Help
Facebook Google Plus
Fibromyalgia  Chronic Fatigue Syndrome & M.E.  Lyme Disease  Natural Wellness  Supplement News  Forums  Our Story
Store     Brands   |   A-Z Index   |   Best Sellers   |   New Products   |   Deals & Specials   |   Under $10   |   SmartSavings Club

Trending News

How Can You Benefit From Vitamin B12?

Discover Why Ashwagandha Can Be Used for Stress and Anxiety

Calorie restriction promotes longevity through effects on mitochondrial network

Higher resveratrol dose linked to lower glucose levels in type 2 diabetics

Tryptophan's Possible Effects for Your Health

What Is Bitter Orange?

Black Tea Is Great for Your Gut

Ashwagandha Helps Hormones - Aids Arthritis

Drug can dramatically reduce weight of people with obesity

New Finding: Broccoli Helps Heal Leaky Gut

 
Print Page
Email Article

Hemispherx Biopharma Releases Preliminary Findings on Ampligen For Treatment of Chronic Fatigue Syndrome at International Conference

  [ 8 votes ]   [ Discuss This Article ]
www.ProHealth.com • February 9, 2001


Hemispherx Biopharma, Inc this week released preliminary findings for the treatment of Chronic Fatigue Syndrome (CFS) with their flagship investigational drug, Ampligen®, under an expanded access program. These findings were first presented at the American Association for Chronic Fatigue Syndrome conference in Seattle, Washington in a peer-reviewed session.
The objective of this study was to review clinical endpoints including Karnofsky Performance Scores (KPS) and Cognitive Function data derived from an expanded access treatment protocol (trial AMP 511) using Ampligen® for the treatment of CFS.

Chronic Fatigue Syndrome is a symptom complex characterized by both cognitive as well as physical impairments. Although the cause of CFS remains under investigation, the presenting symptoms have been codified by the Centers for Disease Control (CDC) and prevention to assist in making a CFS diagnosis. The primary and most salient feature of CFS is persistent and pervasive fatigue and a decrease in physical performance.

Accordingly, the investigators utilized several Quality of Life (QOL) instruments, including the Karnofsky Performance Score (KPS), as well as a self-reported and physician completed instrument evaluating functionality, as endpoints assessing the clinical benefit of Ampligen®. Clinical endpoints included changes in KPS, cognitive deficit (SCL-90-R), and vitality (SF-36) during 24 to 64 weeks of therapy in this expanded access program with cost recovery (AMP 511). An activity monitor was also utilized in a subset of patients to help evaluate changes in physical activity during the study. Ampligen® dosing (200 to 400 mg twice weekly) and data collection intervals (every 8 weeks) were maintained during the study. Data from 41 severely debilitated FS patients who have received at least 16 weeks of Ampligen® treatment, an investigational drug agent, were available and included in the analyses.

The preliminary findings suggested the KPS increased from a median of 50 at Baseline before treatment to 60 by week 24. The median change in KPS from Baseline was +10 points at weeks 16 and 24. Thirteen patients were entered into an extension phase of the study and received at least 64 weeks of investigational drug Ampligen® treatment. For these thirteen severely debilitated CFS patients, KPS increased from a median of 50 at Baseline to 70 by week 64. The median change in KPS from Baseline was +20 KPS points (weeks 32 - 56) and +30 KPS points (week 64). Significant changes in cognitive deficit, vitality and activity monitor scores were also reported by week 24. The investigational drug treatment long-term was generally well tolerated and the majority of patients (>80%) entered the extension phase of the study receiving treatment beyond 24 weeks.



Post a Comment

Featured Products From the ProHealth Store
Ultra ATP+, Double Strength FibroSleep™ Mitochondria Ignite™ with NT Factor®


Article Comments



Be the first to comment on this article!

Post a Comment


 
Optimized Curcumin Longvida with Omega-3

Featured Products

Ultra EPA  - Fish Oil Ultra EPA - Fish Oil
Ultra concentrated source of essential fish oils
Mitochondria Ignite™ with NT Factor® Mitochondria Ignite™ with NT Factor®
Reduce Fatigue up to 45%
FibroSleep™ FibroSleep™
The All-in-One Natural Sleep Aid
Energy NADH™ 12.5mg Energy NADH™ 12.5mg
Improve Energy & Cognitive Function
Optimized Curcumin Longvida® Optimized Curcumin Longvida®
Supports Cognition, Memory & Overall Health

Natural Remedies

Curcumin - a Golden Gift of Nature with Benefits Still Untold Curcumin - a Golden Gift of Nature with Benefits Still Untold
Break Free From Fibromyalgia Break Free From Fibromyalgia
Anti-Inflammatory Properties of Tart Cherry Anti-Inflammatory Properties of Tart Cherry
Joint Aches May Have Met Their Match in Curcumin Joint Aches May Have Met Their Match in Curcumin
The Most Powerful Natural Antioxidant Discovered to Date - Hydroxytyrosol The Most Powerful Natural Antioxidant Discovered to Date - Hydroxytyrosol

CONTACT US
ProHealth, Inc.
555 Maple Ave
Carpinteria, CA 93013
(800) 366-6056  |  Email

· Become a Wholesaler
· Vendor Inquiries
· Affiliate Program
SHOP WITH CONFIDENCE
Credit Card Processing
SUBSCRIBE TO OUR NEWSLETTERS
Get the latest news about Fibromyalgia, M.E/Chronic Fatigue Syndrome, Lyme Disease and Natural Wellness

CONNECT WITH US ProHealth on Facebook  ProHealth on Twitter  ProHealth on Pinterest  ProHealth on Google Plus

© 2017 ProHealth, Inc. All rights reserved. Pain Tracker App  |  Store  |  Customer Service  |  Guarantee  |  Privacy  |  Contact Us  |  Library  |  RSS  |  Site Map